{"product_id":"mesenchymal-stem-cells-medicinal-signaling-cells-mscs-advances-applications-2023","title":"Mesenchymal Stem Cells \/ Medicinal Signaling Cells (MSCs) – Advances \u0026 Applications, 2023","description":"\u003cp\u003eMesenchymal Stem Cells \/ Medicinal Signaling Cells (MSCs) – Advances \u0026amp; Applications, 2023\u003c\/p\u003e\n\n\u003cp\u003eExecutive Summary\u003c\/p\u003e \n\n\u003cp\u003eMSCs are multipotent cells that can differentiate into a variety of cell types, including but not limited to osteoblasts, chondrocytes, myocytes, and adipocytes. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are advantageous over other cell types for a variety of reasons, including that they are immuno-evasive, making them an advantageous cell type for allogenic transplantation.\u003c\/p\u003e\n\n\u003cp\u003eMSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expandability, transplantability, and ethical implications. Interest in therapeutic applications of human MSCs arises from their diverse ability to impact human health, as well as their ability to migrate to sites of tissue injury\/inflammation or tumor growth.\u003c\/p\u003e\n\n\u003cp\u003eMSCs are essential raw materials for many regenerative medicine products, including cell-based therapies, engineered tissues, exosome products, cosmeceuticals, and cultured meat production. MSCs are also well-suited for use in the exponential growth field of 3D printing and numerous companies are working on manufacturing technologies to support the commercial-scale production of MSCs.\u003c\/p\u003e\n\n\u003cp\u003eToday, numerous market competitors are also exploring commercialization strategies for MSC-derived extracellular vesicles (EVs) and exosomes, because these extracellular “packages” represent a novel strategy for accessing the therapeutic effects of MSCs without the risks of administering whole cells to patients. Gene editing of MSCs for overexpressing antitumor genes or therapeutic factors is broadening their application as well.\u003c\/p\u003e \n\n\u003cp\u003eDespite the challenges associated with commercializing MSC-based therapeutics, there are more than 100,000 scientific publications published about MSCs and over 1,100 MSC-based clinical trials underway worldwide. Clinical trials involving MSC therapeutics have risen in recent years, in part due to trials related to COVID-19. Current “hotspots” for MSC clinical trials include the U.S., E.U., China, Middle East, and South Korea. While many early-stage MSC trials have demonstrated safety and efficacy, only a small number of MSC products have reached commercialization, indicating that the therapeutic market for MSCs remains early-stage. The first MSC-based cell therapy product was approved in 2010 in South Korea. To date, ten MSC-based cell therapy products have gained approval, as well as 19 MSC-based bone matrices.\u003c\/p\u003e\n\n\u003cp\u003eWhile therapeutic success has been challenging, the demand for MSC-based research products has surged in recent years, with most large research product suppliers now offering a variety of MSC-based products, services, kits, and manufacturing tools. Major players involved in the market for MSC-based research products include Lonza, Thermo Fisher Scientific, Sigma Aldrich, VWR, Sartorius, ATCC, EMD Millipore, and others. Smaller and mid-sized players are also competing in this promising market, including but not limited to Axol Bioscience, StemBioSys, PromoCell, and iXCell Biotechnologies. To date, the company to establish itself with the greatest domain knowledge in the area of MSC-based products and manufacturing technologies is RoosterBio, headquartered in Frederick, Maryland, USA.\u003c\/p\u003e \n\n\u003cp\u003eCynata Therapeutics is also working diligently on technologies to enable large-scale production of MSC-based therapeutics, although it is exclusively focused on MSC-based therapeutics and is using its Cymerus™ platform technology to produce nearly infinite numbers of iPSC-derived MSCs. It is concurrently pursuing several clinical trials worldwide. In the coming years, an increasing number of research products and therapeutic products will continue to be developed around MSCs and their differentiated cell types.\u003c\/p\u003e\n\n\u003cp\u003eWithin this rapidly changing landscape, having a thorough understanding of the competition is essential. Therefore, this global strategic report details the activities of 113 leading MSC companies, including their core technologies and products under development. It presents detailed market size figures for the global MSC market, segmented by Geography and Business Segment, and accompanied by future forecasts through 2030.\u003c\/p\u003e \n\n\u003cp\u003eThis global strategic report includes:\u003c\/p\u003e\n\n\u003cp\u003eMarket size determination for the global MSC market, segmented by Geography and Business Segment\u003cbr\u003e\nFuture forecasts for the Global MSC Market through 2030\u003cbr\u003e\nMajor diseases addressed by MSCs in the ongoing clinical trials\u003cbr\u003e\nCost of manufacturing autologous and allogeneic MSCs\u003cbr\u003e\nRates, quantities, geographic locations, and types of MSC clinical trials\u003cbr\u003e\nTypes and sources of MSC industry funding\u003cbr\u003e\nDetailed MSC patent analysis, including rates and geographic breakdown of MSC patents \u003cbr\u003e\nThe top owners, inventors, and sponsors of MSC patents\u003cbr\u003e\nRecent business developments related to MSCs, including strategic collaborations and partnerships \u003cbr\u003e\nMSC-based products with marketing approval and the companies commercializing them\u003cbr\u003e\nCurrently marketed MSC-based bone matrices\u003cbr\u003e\nPricing comparison of MSC-based products with marketing approval\u003cbr\u003e\nThe pipeline for MSC-based therapeutics \u003cbr\u003e\nEmerging applications for MSCs, including genetic modification, 3D bioprinting, clean meat production, and cosmeceuticals\u003cbr\u003e\nCompany profiles for MSC market competitors, including their products, services, and technologies under development\u003cbr\u003e\nDozens of charts, figures, and tables \u003cbr\u003e\nAnd so much more\u003c\/p\u003e\n\n\u003cp\u003eIn summary, this global strategic report presents market size figures with forecasts through 2030, as well as rates of MSC clinical trials, scientific publications, patents, funding events, and strategic collaborations. It also presents the pipeline for MSC-based therapeutics, identifies leading market competitors, and explores future directions for the industry at large. With the competitive nature of this global market, you don’t have the time to do the research. Claim this report to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"May, 2023 \/ 351 Pages \/ MCW16229744","offer_id":47646997315890,"sku":null,"price":5156.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/mesenchymal-stem-cells-medicinal-signaling-cells-mscs-advances-applications-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}